Vascular Injury Treatment Market

Executive Summary

Vascular Injury Treatment Market was valued at US $3.23 billion in 2021 and is projected to grow at 6.39% CAGR over the forecast period to reach US $4.69 billion by 2027. Vascular Injury Treatment Market represented US $0.38 billion opportunity over 2019-2021 and estimated to create US $1.45 billion opportunity in 2027 over 2021.

Vascular Injury Treatment from Consainsights analyses the Vascular Injury Treatment Market in the Life Sciences industry over the forecast period to 2027.

Vascular Injury Treatment research report from Consainsights outlines the detailed strategic analysis, trends, market opportunities, growth prospects, industry and market challenges and sustainable solutions to sustain in the competitive environment.

Vascular Injury Treatment segmentation includes Treatment, Injury and Geography.

Based on the Treatment, the Vascular Injury Treatment analysis covers Patch Angioplasty, Lateral Arteriorrhaphy/ Venorrhaphy, Bypass Graft, Thrombectomy, Extraanatomic Bypass, Others.

In Treatment segment, Patch Angioplasty segment has highest cagr growth of 5.66%.

Based on the Injury, the Vascular Injury Treatment analysis covers Thrombosis, Contusion/Intimal Flap, Laceration/Transection, Spasm, Aneurysm and Pseudoaneurysm, Arteriovenous (AV) Fistula, Others.

In Injury segment, Thrombosis segment has highest cagr growth of 5.66%.

Based on the region, the Vascular Injury Treatment analysis covers North America, Europe, Asia-Pacific, Middle-East & Africa, Latin America.

Key companies operating in the market include Cleveland Clinic, Massachusetts General Hospital, Heidelberg University Hospital, Royal Berkshire NHS Foundation Trust, Mayo Clinic Health System, Tenet Healthcare, Apollo Hospitals Enterprise Ltd., Universal Health Services, Inc., Mediclinic International, CHSPSC, LLC and so on. This report covers the detailed analysis of the company profiles such as business segments, product portfolio, key brand insights and growth strategies adopted, company SWOT and Strategy analysis along with the financial analysis and analyst insights on the key companies operating in this market.

Market Overview

Definition & Scope

The base currency considered was the US Dollar (USD). Conversion of other currencies to USD was considered on the basis of the average exchange rate for the respective review-period years. The exchange rate conversion for forecast period was determined according to the base year’s conversion rates.

The base year was identified based on the availability of annual reports and secondary information. The base year considered for this study is 2027.

The review period considered for this study is from 2018-2027. The CAGR is for the forecast period, 2022-2027.

Market size estimations for the forecast years were in real terms. Inflation is not part of the pricing, and the average selling price (ASP) was kept constant throughout the forecast period for each country.

Distribution of primary interviews conducted was based on the regional share of the market and the presence of key players in each region.

As a result of data triangulation through multiple methodologies and approaches, the weighted averages of resulting estimates were considered to be the final values.

Currency, Year & Forecast

The currency used in this report is USD, with the market size indicated in terms of USD million/billion.

For companies reporting their revenues in USD, the revenues were taken from their respective annual reports/SEC filings.

For companies reporting their revenues in other currencies, the average annual currency conversion rates were used for a particular year to convert the value to USD Market Definition.

Treatment

Introduction

In 2021, Patch Angioplasty segment has the highest revenue of US $1.29 billion and is expected to grow at CAGR of 5.66% by 2027 Patch Angioplasty segment has highest cagr growth of 5.66%.

Patch Angioplasty

Patch Angioplasty segment was valued at US $1.14 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $1.86 billion by 2027. Patch Angioplasty segment represented US $0.15 billion opportunity over 2019-2021 and estimated to create US $0.58 billion opportunity in 2027 over 2021.

Lateral Arteriorrhaphy/ Venorrhaphy

Lateral Arteriorrhaphy/ Venorrhaphy segment was valued at US $0.71 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $1.17 billion by 2027. Lateral Arteriorrhaphy/ Venorrhaphy segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.36 billion opportunity in 2027 over 2021.

Bypass Graft

Bypass Graft segment was valued at US $0.50 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $0.83 billion by 2027. Bypass Graft segment represented US $0.07 billion opportunity over 2019-2021 and estimated to create US $0.26 billion opportunity in 2027 over 2021.

Thrombectomy

Thrombectomy segment was valued at US $0.24 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $0.40 billion by 2027. Thrombectomy segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.12 billion opportunity in 2027 over 2021.

Extraanatomic Bypass

Extraanatomic Bypass segment was valued at US $0.12 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $0.20 billion by 2027. Extraanatomic Bypass segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.06 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $0.15 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $0.24 billion by 2027. Others segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.07 billion opportunity in 2027 over 2021.

Injury

Introduction

In 2021, Thrombosis segment has the highest revenue of US $1.34 billion and is expected to grow at CAGR of 5.66% by 2027 Thrombosis segment has highest cagr growth of 5.66%.

Thrombosis

Thrombosis segment was valued at US $1.19 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $1.95 billion by 2027. Thrombosis segment represented US $0.16 billion opportunity over 2019-2021 and estimated to create US $0.60 billion opportunity in 2027 over 2021.

Contusion/Intimal Flap

Contusion/Intimal Flap segment was valued at US $0.72 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $1.18 billion by 2027. Contusion/Intimal Flap segment represented US $0.09 billion opportunity over 2019-2021 and estimated to create US $0.37 billion opportunity in 2027 over 2021.

Laceration/Transection

Laceration/Transection segment was valued at US $0.47 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $0.78 billion by 2027. Laceration/Transection segment represented US $0.06 billion opportunity over 2019-2021 and estimated to create US $0.24 billion opportunity in 2027 over 2021.

Spasm

Spasm segment was valued at US $0.23 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $0.38 billion by 2027. Spasm segment represented US $0.03 billion opportunity over 2019-2021 and estimated to create US $0.12 billion opportunity in 2027 over 2021.

Aneurysm and Pseudoaneurysm

Aneurysm and Pseudoaneurysm segment was valued at US $0.14 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $0.23 billion by 2027. Aneurysm and Pseudoaneurysm segment represented US $0.02 billion opportunity over 2019-2021 and estimated to create US $0.07 billion opportunity in 2027 over 2021.

Arteriovenous (AV) Fistula

Arteriovenous (AV) Fistula segment was valued at US $0.06 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $0.10 billion by 2027. Arteriovenous (AV) Fistula segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.03 billion opportunity in 2027 over 2021.

Others

Others segment was valued at US $0.04 billion in 2019 and is projected to grow at 5.66% CAGR over the forecast period to reach US $0.07 billion by 2027. Others segment represented US $0.01 billion opportunity over 2019-2021 and estimated to create US $0.02 billion opportunity in 2027 over 2021.